Patents Assigned to ThromboGenics NV
-
Publication number: 20190031762Abstract: The disclosure is situated in the field of ocular therapies. In particular, in some embodiments the disclosure provides antagonists of placental growth factor and related methods of use for treating, preventing, or delaying posterior ocular fibrosis. In other embodiments, the disclosure provides monospecific placental growth factor (PlGF) antagonist compositions and related methods for maintaining or improving visual acuity of a subject with an eye of which the retina is damaged.Type: ApplicationFiled: March 10, 2017Publication date: January 31, 2019Applicant: THROMBOGENICS NVInventors: Tine Van Bergen, Bart Jonckx, Jean Feyen
-
Patent number: 9884910Abstract: The invention relates to antibodies binding to the PDGF-C antigen and capable of inhibiting binding of PDGF-C to the PDGFR? receptor and of inhibiting PDGFR? activation by PDGF-C. Applications of such antibodies are also disclosed. These include treatment of cancer.Type: GrantFiled: April 24, 2013Date of Patent: February 6, 2018Assignee: ThromboGenics NVInventors: Claudia Fromond, Hoa Thu Ngo, Richard Zwaal, Sofie Notebaert
-
Patent number: 9770494Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: June 27, 2014Date of Patent: September 26, 2017Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet
-
Patent number: 9644196Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatalytic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: GrantFiled: August 13, 2012Date of Patent: May 9, 2017Assignee: ThromboGenics NVInventor: Richard Reinier Zwaal
-
Patent number: 9445078Abstract: This invention concerns a measuring system for the calculation of dimensions, including area and volume, of objects in various shapes. In particular, it concerns miniature 3D measuring equipment that is perfectly suitable for 3D measurements of subcutaneous tumors in mice. The primary objective of this invention then also consists of a measuring system for 3D measurements of objects in various shapes, which includes a handheld device that has at least 1 camera, 1 projector and a measuring chamber. In another implementation, the handheld device will have 2 cameras and a projector and the 3D measurement is based on stereo-vision. Another objective is directed to ensuring that said handheld device also has a processor module, a user interface, a power supply, a data communication interface, and exchangeable measuring chambers which provide the flexibility and autonomy to speed up the measurement procedure, and significantly improve the reproducibility of the measurement.Type: GrantFiled: April 27, 2012Date of Patent: September 13, 2016Assignees: ThromboGenics NV, Peira BVBAInventors: Emmanuel Sneyders, Jean Marie Stassen, Hans Nicasy
-
Patent number: 9226953Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: GrantFiled: July 9, 2010Date of Patent: January 5, 2016Assignee: ThromboGenics NVInventor: Richard Reinier Zwaal
-
Patent number: 9186394Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: March 14, 2013Date of Patent: November 17, 2015Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet
-
Patent number: 9089552Abstract: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof.Type: GrantFiled: March 13, 2013Date of Patent: July 28, 2015Assignee: ThromboGenics NVInventors: Bart Jonckx, Tine Van Bergen, Ingeborg Stalmans
-
Patent number: 8920794Abstract: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these.Type: GrantFiled: August 16, 2013Date of Patent: December 30, 2014Assignee: ThromboGenics NVInventors: Jean-Marie Stassen, Ingeborg Stalmans
-
Patent number: 8834869Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: November 29, 2012Date of Patent: September 16, 2014Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet
-
Publication number: 20140205588Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatalytic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: ApplicationFiled: August 13, 2012Publication date: July 24, 2014Applicant: THROMBOGENICS NVInventor: Richard Reinier Zwaal
-
Patent number: 8747842Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: April 29, 2011Date of Patent: June 10, 2014Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet
-
Publication number: 20140111621Abstract: This invention concerns a measuring system for the calculation of dimensions, including area and FIG. 4 volume, of objects in various shapes. In particular, it concern miniature 3D measuring equipment that is perfectly suitable for 3D measurements of subcutaneous tumours in mice. The primary objective of this invention then also consists of a measuring system for 3D measurements of objects in various shapes, which includes a handheld device that has at least 1 camera, 1 projector and a measuring chamber. In a more specific implementation, the handheld device will have 2 cameras and a projector and the 3D measurement is based on stereo-vision.Type: ApplicationFiled: April 27, 2012Publication date: April 24, 2014Applicants: THROMBOGENICS NV, PEIRA BVBAInventors: Emmanuel Sneyders, Jean Marie Stassen, Hans Nicasy
-
Publication number: 20140099710Abstract: The present invention is directed to a method of deriving pluripotent embryonic stem cells from mouse blastocysts or from primordial germ cells from a post-implantation mouse embryo, or of maintaining or growing pluripotent embryonic stem cells from a mouse, or of expanding human hematopoietic stem cells or human hematopoietic precursor cells. The methods include the step of cultivating the stem cells or precursor cells for at least one passage in a culture medium preconditioned by the rabbit fibroblast cell line Rab9 (ATCC catalogue CRL1414) and containing less than 0.1 ng/ml Leukemia Inhibitory Factor (LIF).Type: ApplicationFiled: September 19, 2013Publication date: April 10, 2014Applicant: ThromboGenics NVInventor: Luc SCHOONJANS
-
Publication number: 20130330318Abstract: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery.Type: ApplicationFiled: August 16, 2013Publication date: December 12, 2013Applicant: ThromboGenics NVInventors: Jean-Marie Stassen, Ingeborg Stalmans
-
Publication number: 20130302304Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Applicant: THROMBOGENICS NVInventor: ThromboGenics NV
-
Publication number: 20130273028Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: ApplicationFiled: January 4, 2012Publication date: October 17, 2013Applicant: ThromboGenics NVInventor: Richard Reinier Zwaal
-
Publication number: 20130202613Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: ApplicationFiled: November 30, 2012Publication date: August 8, 2013Applicant: THROMBOGENICS NVInventor: ThromboGenics NV
-
Publication number: 20130195889Abstract: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: THROMBOGENICS NVInventor: ThromboGenics NV
-
Publication number: 20130195887Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: ApplicationFiled: November 29, 2012Publication date: August 1, 2013Applicant: THROMBOGENICS NVInventor: ThromboGenics NV